Zhejiang East-Asia Pharmaceutical (SH:605177) 智通财经网·2026-01-22 08:28Core Viewpoint - East Asia Pharmaceutical (605177.SH) forecasts a net loss attributable to shareholders of 75 million to 90 million yuan for the fiscal year 2025 [1] Group 1: Financial Performance - The company anticipates a net loss of 75 million to 90 million yuan for 2025 [1] Group 2: Product Development - During the reporting period, the company has applied for a batch of new approvals for raw materials and formulations [1] - The company has obtained its first formulation approval for Levofloxacin tablets, marking a significant breakthrough in its integrated development strategy of raw materials and formulations [1] - This approval will enrich the company's product line, enhance its competitiveness, and promote sustainable, stable, and healthy development [1] - The experience gained from this approval will be valuable for future formulation registration certificate applications [1]